$0.91
+0.05 (+5.70%)
Open$0.89
Previous Close$0.86
Day High$0.92
Day Low$0.89
52W High$2.95
52W Low$0.70
Volume—
Avg Volume43.6K
Market Cap4.60M
P/E Ratio—
EPS$-4.77
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+2,217.3% upside
Current
$0.91
$0.91
Target
$21.09
$21.09
$14.27
$21.09 avg
$34.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.26M | 557.3K | 516.3K |
| Net Income | -195,281,487 | 76.7K | 85.4K |
| Profit Margin | -1,132.4% | 13.8% | 16.5% |
| EBITDA | -148,224,927 | 122.1K | 108.8K |
| Free Cash Flow | — | 55.8K | 59.0K |
| Rev Growth | +166.9% | +2.4% | +15.9% |
| Debt/Equity | 0.21 | 0.52 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |